Anterior chamber paracentesis after central retinal artery occlusion: a tenable therapy? by unknown
Fieß et al. BMC Ophthalmology 2014, 14:28
http://www.biomedcentral.com/1471-2415/14/28RESEARCH ARTICLE Open AccessAnterior chamber paracentesis after central retinal
artery occlusion: a tenable therapy?
Achim Fieß1*, Ömer Cal1, Stephan Kehrein1, Sven Halstenberg1, Inez Frisch2 and Ulrich Helmut Steinhorst2Abstract
Background: The goal of this study was to investigate the visual outcome of acute central retinal artery occlusion
(CRAO) after current standard therapy with and without paracentesis. In addition, we investigated whether there
was a dependence of the resulting visual acuity on the time between first symptoms and implementation of
paracentesis. Finally, we analysed risk factors for CRAO.
Methods: We performed a retrospective analysis of data from patients with CRAO who received standard in-patient
therapy with and without paracentesis at the Dr. Horst Schmidt Clinics in Wiesbaden, Germany between 2000 and
2012. The primary endpoint was the change of visual acuity 3 days after the initiation of intervention.
Results: Data from 74 patients with CRAO were included in the study. Fifteen patients were treated conservatively
and 59 patients received additional paracentesis. Clinically significant improvement of BCVA (logMAR ≥ 0.3) after
3 days was observed in 26.7% of patients without paracentesis, 36.4% of patients with paracentesis within 6 hours,
20% of patients with paracentesis within 7–24 hours, and 23.1% of patients with paracentesis more than 24 hours after
the onset of symptoms. There was no significant difference in the outcome between patients with (BCVA 1.9 ± 0.31)
and without paracentesis (BCVA 1.75 ± 0.32) (p = 0.9), nor among the groups with paracentesis (p = 0.8). One patient
suffered a lens injury due to the paracentesis, with subsequent need for cataract surgery.
Conclusions: There was no added gain in visual acuity by performing a paracentesis, independent of the time elapsed
between first symptoms and the implementation of paracentesis. In the absence of any tangible effectiveness of
paracentesis and the inherent risks of paracentesis such as intraocular infection and injury, paracentesis does not
appear to be warranted as a treatment of CRAO.
Keywords: Central retinal artery occlusion, Intraocular pressure, Paracentesis, Retinal vascular occlusion, TreatmentBackground
Acute central retinal artery occlusion (CRAO) is an oph-
thalmological emergency caused by closure of the
central retinal artery by a thrombus or embolus [1,2].
Clinically, the patient notices a sudden and painless
unilateral loss of vision. Even if there is only a short
closure of the central retinal artery, CRAO leads to per-
manent ischaemic damage of the retina. Therapy ap-
proaches described in the medical literature include
systemic anticoagulation [3], systemic venous thromb-
olysis [4,5], catheter-guided intra-arterial fibrinolysis
[3], ocular massage [2,3] and reduction of intraocular
pressure [2,6,7].* Correspondence: achim.fiess@hsk-wiesbaden.de
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unless otherwise stated.Despite the numerous therapeutic approaches there is
no effective therapy to date that restores function of the
retina to a satisfying extent. Reduction of intraocular
pressure to improve intraocular blood flow is frequently
discussed as a possible treatment option. Approaches to-
ward lowering intraocular pressure include administra-
tion of systemic [7,8] and local [3] medications, ocular
massage [2,3], and paracentesis [6,9].
Several studies have shown that the retina only has a
very short tolerance for ischaemia, which was deter-
mined to be 105 minutes in animal experiments [10-12].
If ischaemic conditions persist longer than this period,
permanent retinal damage seems inevitable. Since the
extent of retinal damage is a function of the duration of
ischaemia, it is important that a countermeasure against
CRAO be effective quickly and available at any time.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Fieß et al. BMC Ophthalmology 2014, 14:28 Page 2 of 7
http://www.biomedcentral.com/1471-2415/14/28Paracentesis leads to a rapid reduction of intraocular
pressure, and therefore is believed to promote retinal
perfusion, especially in the first hours after CRAO [7,9].
Advantages of paracentesis are that the implementation
is quick and involves low costs and few resources. On
the other hand, paracentesis poses a considerable risk of
infection.
Most studies regarding the medical benefit of paracen-
tesis examined only whether there is a gain in visual acu-
ity for patients with CRAO after paracentesis, but did
not consider the time between first symptoms and the
initiation of therapy [9]. In the present study we investi-
gated whether paracentesis improves visual acuity after
CRAO depending on the time between first symptoms
of CRAO and the implementation of paracentesis. Fur-
thermore, we analysed the predictive value that frequent
risk factors for CRAO might have. These risk factors
include arterial hypertension [13,14], hypercholesterol-
aemia [15], atherosclerosis [16], afflictions of the carotid
arteries [17], cardiac arrhythmias [15], and diabetes mel-
litus [18]. Overall, this study aims to address the ques-
tion of whether the benefits of paracentesis justify the
associated risks.
Methods
We performed a retrospective analysis of data from
patients with CRAO treated between 2000 and 2012 with
standard in-patient therapy with or without paracentesis.
All patients received the same conservative therapy and
the group of patients with paracentesis received addition-
ally a paracentesis that was conducted in addition to the
conservative treatment after the diagnosis was found.
Diagnosis was based on funduscopic evaluation by the
treating ophthalmologist and positive identification of typ-
ical CRAO characteristics such as a cherry-red spot in the
macula and a reduction in arterial blood flow (Figure 1).Figure 1 Typical central retinal artery occlusion with cherry-red
spot, retinal oedema and narrowing of the vessels.Arteritic aetiology was excluded by the absence of
elevated inflammatory parameters and verification of
the typical clinical presentation of CRAO. In the present
study we only included patients with non-arteritic CRAO
with thromboembolic origin. Arteritic, transient ischaemia
and CRAO with a preserved cilioretinal vessel were ex-
cluded. Additionally, the time between first symptoms and
implementation of the paracentesis had to be traceable.
All patients were treated in an in-patient setting. Standard
treatment consisted of routine anticoagulation with low
molecular weight heparin adjusted to patient body weight
twice daily, bloodletting for hematocrit ≥40%, and para-
centesis in certain cases.
Paracentesis included local anaesthesia with proxyme-
tacaine hydrochloride, application of prophylactic anti-
biotic eye drops, and a brief puncture of the cornea with
a paracentesis blade to drain a few drops of aqueous
fluid. Successful execution was verified with an applana-
tory intraocular pressure measurement that had to be
under 5 mmHg. In case of contraindications or a decline
by the patient, paracentesis was waived.
Best corrected visual acuity (BCVA) was measured at
the beginning of treatment and after 3 days. In addition,
we recorded current medication, demographic data, the
onset of initial CRAO symptoms, and the time of para-
centesis. Furthermore, an analysis of cardiovascular risk
factors was performed and the test results were docu-
mented. In particular, blood pressure was measured rou-
tinely four times during the first 24 hours. The average
of these measurements was used for the statistical ana-
lysis of the blood pressure at the beginning of therapy.
Finally, any complications associated with paracentesis
were documented.
The data collection in this study has been performed in
accordance with the Declaration of Helsinki. Because of the
retrospectivity of the study and complete anonymisation of
patient data, ethics committee approval was not required
[19]. The data collection complied with all applicable insti-
tutional, national and international guidelines.
Data analysis and end points
The primary endpoints were the change in visual acuity
3 days after the beginning of treatment and the time be-
tween first symptoms and initiation of therapy.
Visual acuity was determined on the basis of numbered
optotypes and converted for the analysis into the logarithm
of the minimum angle of resolution (logMAR). This was
carried out for all visual acuities ≥1/250. If visual acuity
was less than 1/250, the following logMAR values were
assigned: counting fingers = 1.9, hand motion = 2.0, light
perception = 2.1, and no light perception = 3.0.
A significant clinical improvement in visual acuity was
defined based on the EAGLE Study [20] as improve-
ment in visual acuity of at least 0.3 log units. Secondary
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paracentesis and the patients’ cardiovascular risk factors.
Statistical analysis
The assumption of a normal distribution of data points
was tested by the Kolmogorov-Smirnov test. The Chi-
square test was used for the statistical comparison of
nominal parameters. The Mann–Whitney U test was used
to compare groups with or without paracentesis. The
Kruskal-Wallis H test was used to compare the different
groups receiving paracentesis. All results were expressed as
mean ± standard deviation, except where otherwise speci-
fied. A value of p < 0.05 was considered statistically signifi-
cant. The incorporation of cardiovascular risk factors into
the statistical analysis was merely descriptive.
Results
This study includes data from 74 patients with CRAO
treated at the Dr. Horst Schmidt Clinics in Wiesbaden
between 2000 and 2012. The patients included 39 males
and 35 females. The mean patient age was 73.9 ±
9.8 years. Fifteen patients were treated conservatively
and 59 patients received additional paracentesis. In
patients receiving paracentesis, the procedure was per-
formed in 11 patients (18.6%) within 6 hours, 35 patients
(59.4%) within 7–24 hours, and 13 patients (22.0%) beyond
24 hours after first symptoms (Table 1).
Starting visual acuity
The BCVA [logMAR] at the start of standard treatment
in the group of patients without paracentesis was 1.92 ±
0.21. The BCVA was 1.96 ± 0.16 for patients with para-
centesis within 6 hours, 1.99 ± 0.25 for patients with
paracentesis within 7–24 hours, and 2.05 ± 0.32 for
patients with paracentesis more than 24 hours after first
symptoms (Table 2). There was no significant differ-
ence between the groups with and without paracentesis
(p = 0.4), nor between groups of patients with paracen-
tesis at different times after onset of CRAO (p = 0.9).Table 1 Overview of patient pool, study parameters, and eva
Parac
≤6 h 7–24 h
Total number of patients [n] 11 35
Male [n (%)] 7 (63.6%) 18 (51.4%)
Right Eye [n (%)] 6 (54.5%) 15 (42.9%)
Age [years] 72.3 ± 13.8 73.5 ± 8.6
Eye pressure at admission [mmHg] 13.6 ± 3.0 15.1 ± 3.1
Time to treatment [h] 4.1 ± 1.2 15.3 ± 6.3
Length of hospital stay [days] 4.6 ± 1.6 3.9 ± 2.1
Bloodletting performed [n (%)] 2 (18.2%) 19 (54.3%)
The p-values indicate no significant differences between patients treated with or wChange in visual acuity and outcome
Changes in visual acuity and outcome are shown in
Table 2. Three days after initiation of treatment the
BCVA was 1.75 ± 0.32 in patients without paracentesis.
In patients that received paracentesis within 6 hours
after first symptoms the BCVA was 1.78 ± 0.21 after
three days of our treatment. In the group of patients
with paracentesis within 7–24 hours after the onset of
CRAO the BCVA was 1.92 ± 0.3 after three days, and in
the group of patients with paracentesis more than
24 hours after first symptoms the BCVA was 1.94 ± 0.39
after three days. There was no significant difference in
the BCVA after three days between patients with and
without paracentesis (p = 0.3) nor between groups of
patients receiving paracentesis at different times after
CRAO (p = 0.2).
The improvement in BCVA after 3 days was −0.17 ±
0.33 in patients without paracentesis and −0.1 ± 0.17 in
patients with paracentesis (Figure 2). There was no sig-
nificant difference between patients with and without
paracentesis (p = 0.9). The improvement was −0.18 ±
0.21 in patients treated with paracentesis within 6 hours
after the first symptoms, −0.07 ± 0.15 in patients with
paracentesis within 7–24 hours, and −0.11 ± 0.19 in pa-
tients with paracentesis 24 hours after first symptoms.
There was no significant difference among the different
groups of patients that underwent paracentesis (p = 0.2).
A clinically significant improvement of BCVA (log-
MAR ≥ 0.3) after 3 days was observed in 26.7% of pa-
tients without paracentesis, 36.4% of patients treated
with paracentesis within 6 hours, 20.0% of patients who
underwent paracentesis within 7–24 hours, and 23.1% of
patients who received paracentesis more than 24 hours
after the onset of symptoms (Table 2). There was no sig-
nificant difference in the outcome between patients with
and without paracentesis (p = 0.9), nor among the different
groups treated with paracentesis (p = 0.8).
In 53.4% of patients without paracentesis the visual
acuity after 3 days of conservative treatment was onlyluation times
entesis No paracentesis
>24 h all pat. all pat. p
13 59 15
9 (69.2%) 34 (57.6%) 5 (33.3%) 0.1
5 (38.5%) 26 (44.1%) 8 (53.3%) 0.5
73.6 ± 11.9 73.3 ± 10.3 76.7 ± 7.6 0.2
16.1 ± 8.7 15 ± 4.8 13.3 ± 3.5 0.2
43.9 ± 4.4 28.2 ± 37.7 24.4 ± 16.0 0.3
3.9 ± 1.7 4.1 ± 1.5 4.9 ± 2.7 0.4
5 (38.5%) 26 (44.1%) 4 (26.7%) 0.2
ithout paracentesis.
Table 2 Visual acuity at the start of therapy and after 3 days
Paracentesis No paracentesis
≤6 h 7–24 h >24 h all pat. all pat. p
Baseline visual acuity [logMAR] 1.96 ± 0.16 1.99 ± 0.25 2.05 ± 0.32 2 ± 0.25 1.92 ± 0.21 0.4
Visual acuity after 3 days [logMAR] 1.78 ± 0.21 1.92 ± 0.3 1.94 ± 0.39 1.9 ± 0.31 1.75 ± 0.32 0.3
Gain of visual acuity [log units] −0.18 ± 0.21 −0.07 ± 0.15 −0.11 ± 0.19 −0.1 ± 0.17 −0.17 ± 0.33 0.9
Visual acuity after 3 days:
-clinically better [n(%)] 4 (36.4%) 7 (20.0%) 3 (23.1%) 14 (23.7%) 4 (26.7%)
-clinically equal [n(%)] 7 (63.6%) 27 (77.1%) 10 (76.9%) 44 (74.6%) 11 (73.3%) 0.9
-clinically worse [n(%)] 0 (0%) 1 (2.9%) 0 (0%) 1 (1.7%) 0 (0%)
The p-values indicate no significant difference in the outcome between all patients with and without paracentesis. There was also no significant difference
between the groups of patients with paracentesis at different times after onset of CRAO.
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or worse was observed in 36.4% of patients after imple-
mentation of paracentesis within 6 hours of first CRAO
symptoms, in 65.7% of patients in the group treated with
paracentesis within 7–24 hours, and in 61.6% of patients
in the group that underwent paracentesis 24 hours after
first symptoms.
Dependence of subsequent visual acuity on the time
between first CRAO symptoms and initiation of treatment
Based on our results, the time elapsed between first
symptoms of CRAO and the start of therapy had no sig-
nificant influence on the outcome of visual acuity in the
group of patients with conservative treatment (p = 0.8) or
in the group treated with paracentesis (p = 0.4) (Figure 3).
Thromboembolic risk factors
The thromboembolic risk factors recorded upon hos-
pitalisation are shown in Table 3. Arterial hyperten-
sion was the most common risk factor. A history of
arterial hypertension was present in 81.1% of patients
at admission. In general, systolic blood pressure during
the first 24 hours after admission was very high. Only
23.0% of patients had systolic blood pressure values in
the normal range (120–139 mmHg), 48.6% had grade 1Figure 2 Average change in visual acuity from time of hospital
admission to three days after initiation of treatment for CRAO.
The p-value of 0.9 indicates no significant difference with respect to
vision improvement between patients treated with or without
additional paracentesis.hypertension (140–159 mmHg), 18.9% had grade 2 hyper-
tension (160–179 mmHg), and 9.5% had grade 3 hyperten-
sion (≥ 180 mmHg).
Overall, a haematocrit ≥ 40% was documented in 40.5%
of all patients, with subsequent implementation of isovo-
laemic haemodilution, 20.3% of patients had a personal
history of hyperlipidaemia, 8.1% suffered from atrial fib-
rillation, 17.6% had a history of diabetes mellitus, and
16.2% reported a previous thromboembolic event. Cor-
onary heart disease or heart valve disease was docu-
mented in 21.6% of patients. No cardiovascular risk
factors were reported by 16.4% of patients. An increased
intraocular pressure (applanatory) above 21 mmHg was
measured in 4.1% of patients. At the time of CRAO,
39.2% of patients were taking acetylsalicylic acid, and
4.1% were taking phenprocoumon.
Complications of paracentesis
Paracentesis was performed without complications in 58
of 59 cases. One patient suffered a lens injury due to the
paracentesis, with subsequent need for cataract surgery.
None of the paracenteses resulted in intraocular infection.
Discussion
The present study reveals no significant benefit of para-
centesis to visual acuity after CRAO regardless of the
time between first symptoms and initiation of therapy.
This agrees with previously published data [9], where
the gain in visual acuity was analysed independently of
the time between CRAO and the onset of treatment.
Moreover, in one case paracentesis led to lens injury re-
quiring subsequent cataract surgery. These observations
raise questions about paracentesis as a tenable treatment
option for patients with CRAO.
One long-standing argument in favour of paracentesis is
that lowering the intraocular pressure leads to a relative
rise in the retinal perfusion pressure, possibly resulting in
improved retinal blood flow. Implementing paracentesis
and draining ocular fluid offers a quick and effective means
Figure 3 Change in visual acuity for patients from time of hospital admission to three days after initiation of CRAO treatment as a
function of the time elapsed between first symptoms and the initiation of therapy. No detectable functional dependence existed between
these two parameters for the group of patients with conservative treatment (p = 0.8) and in the group treated with paracentesis (p = 0.4).
Fieß et al. BMC Ophthalmology 2014, 14:28 Page 5 of 7
http://www.biomedcentral.com/1471-2415/14/28to lower the intraocular pressure. In addition, this proced-
ure is inexpensive and can be performed readily by any
ophthalmologist with minimal preparation. On the other
hand, an argument against paracentesis is the possibility of
injuries to eye structures of the anterior segment as well as
the risk of infections. In previous studies a gain in visual
acuity due to paracentesis could not be proven [6,9]. Exper-
iments showed that a decrease in intraocular pressure from
15 mmHg to 5 mmHg resulted in a relative increase of the
perfusion pressure of only 15% and an increase of arterial
blood flow of only 20% [7,9].
As a result of the retina’s low ischaemic tolerance, irre-
versible retinal damage occurs shortly after arterial oc-
clusion [10-12]. Based on clinical data, it is assumed
that visual acuity can recover partially up to 48 hoursTable 3 Cardiovascular risk factors among patients with CRAO
Paracentes
≤ 6 h 7–24 h
(%) (%)
Arterial hypertension 81.8 82.9
Hyperlipidaemia 36.4 20.0
Diabetes mellitus 9.1 14.3
Atrial fibrillation 9.1 2.9
CHD/valvular heart disease 9.1 28.6
History of embolic event 18.2 11.4
The p-values indicate that the distribution of risk factors was random and evenly diafter blood vessel closure [21]. Schumacher et al. [3]
showed a relationship between the eventual visual acu-
ity and the time from arterial occlusion to the initi-
ation of treatment. The study concluded that a delay
in treatment within the first 20 hours after CRAO re-
sulted in an irreversible loss of visual acuity of 0.2
lines per hour delay.
Contrary to this study, our data revealed no im-
provement of mean visual acuity in patients undergo-
ing paracentesis within 6 hours of the first symptoms
of CRAO relative to those undergoing paracentesis
6–24 hours or longer after the first symptoms. In agree-
ment with the present data, Augsburger et al. [6] found
that only 35% of patients with persistent CRAO showed
a clinically significant improvement of visual acuity ofin this study
is No paracentesis
>24 h all pat. all pat. p
(%) (%) (%)
76.9 81.4 80.0 0.9
23.1 23.7 13.3 0.6
15.4 13.6 33.3 0.1
7.7 5.1 20.0 0.1
15.4 22.0 20.0 0.9
15.4 13.6 26.7 0.2
stributed among the patients with and without paracentesis.
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tients showed an improvement of visual acuity of more
than 0.1 [22,23].
In 92% of patients without therapy, the visual acuity
after CRAO is counting fingers or worse [24]. Hayreh
and colleagues [24] demonstrated that any possible in-
crease of visual acuity after CRAO usually occurs within
the first week or within the first few days after the occlu-
sion. It was shown, that a clinically significant increase
in visual acuity after weeks is rare [25]. Therefore, it is
unlikely in our study that any significant relative im-
provement of visual acuity might have occurred beyond
our follow-up time of 3 days among the patients treated
with paracentesis. The most obvious explanation for
the low visual acuity after CRAO is that current ther-
apies do not yield the desired therapeutic success, and to
date no sufficient therapy is available. The evaluation of
possible therapies for CRAO is difficult because the ef-
fects of possible treatment options were often tested only
in non-randomised and/or retrospective interventional
studies. Previous studies served as the only reference.
Due to the low incidence of CRAO, which is only
about 8.5 per 100,000 [2], there is also the problem of
small case numbers for any randomised interventional
study. The EAGLE Study [20] achieved a recruitment of
only 84 patients over a period of 5 years. In two of the
largest studies patients were included over a 30 year
period [26,27]. The present study spanned 13 years.
Limitations of the study are a potential selection bias,
short Follow-Up and the lack of angiographic examin-
ation after three days to evaluate whether the paracen-
tesis improved retinal arterial perfusion even without
visual improvement.
With no effective treatment for CRAO available it is
important to identify the causes and focus on preventive
measures. Cardiovascular mortality rate of affected pa-
tients was also shown to increase when risk factors for
CRAO were ignored [28]. Therefore, diagnosis and
adequate treatment of cardiovascular risk factors is of
utmost importance. In 64–82% of patients with CRAO
at least one previously undetected cardiovascular risk
factor was diagnosed in the wake of a thromboembolic
risk check-up [29]. Furthermore, 54% of patients with
CRAO were under inadequate or no treatment of arter-
ial hypertension, or suffered from a previously un-
detected, haemodynamically significant carotid stenosis
[29]. This is consistent with our observation that systolic
blood pressure during the first 24 hours of hospitalisa-
tion was significantly elevated in 77% of CRAO patients.
Since it is widely thought that hypertension is a major
risk factor for CRAO and other serious cardiovascular
conditions, there is ample and compelling reason from
an opthalmological point of view to control blood pres-
sure tightly and aggressively.Antiplatelet agents are used in neurology for protec-
tion against intracranial embolism. Accordingly, patients
with CRAO are expected to benefit from such medica-
tions and avoid CRAO in the unaffected eye. However,
the present study revealed that CRAO occurred in al-
most half of all patients taking the anticoagulants acetyl-
salicylic acid or phenprocoumon.
Conclusion
We conclude that paracentesis is not recommendable as
a therapy for CRAO at any time point after the arterial
occlusion. This is based on the absence of any statisti-
cally significant improvement of visual acuity over con-
servative treatments, and the risks of endophthalmitis
and injury to structures of the anterior segment associ-
ated with paracentesis. Due to the difficulties in prevent-
ing and treating CRAO reliably, this ophthalmological
emergency continues to be an unpredictable and tragic
event for anyone affected by it. Therefore, special em-
phasis and care should be dedicated to the interdis-
ciplinary collaboration between general practitioner and
ophthalmologist following a CRAO. The primary goal
must be a comprehensive investigation of a patient’s indi-
vidual risk factors for CRAO and their subsequent treat-
ment. This should contribute to reducing mortality after
CRAO and prevent the occurrence of CRAO in the un-
affected eye.
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